A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants
Latest Information Update: 05 Oct 2025
At a glance
- Drugs Brenipatide (Primary) ; Brenipatide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 05 Oct 2025 New trial record